Sun Pharma signs in-licensing deal to sell skincare drug in US

Acne, being the most prevalent skin condition in the US, affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new mechanism of action (MOA) occurred nearly 40 years ago. Winlevi is expected to be available in the US in Q4 calendar 2021, added the statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3BE0QcJ
via IFTTT